BridgeMD
Staging of gastric cancers by PET-FAPI
EU CTIS ID: 2025-524434-25-00
What this study is testing
In the study target population (stage ≥ II gastric adenocarcinomas or signet-ring cells adenocarcinomas of any stage, eligible for curative treatment), estimate the proportion of patients who present an appropriate change of TNM classification following the addition of 68Ga-FAPI-46 PET-CT to the reference examinations, during the initial staging (including laparoscopy)
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Gastric cancer: stage ≥ II gastric adenocarcinoma or signet-ring cell adenocarcinoma whatever the stage, potentially requiring curative treatment
- Age > 18 years old at time of signed consent
- Beneficiary of social security insurance
- Signed informed consent by the participant and the investigator
You likely can't join if
- Tumor M+ or with suspicion of distant metastasis on standard assessment
- Person deprived of liberty by judicial or administrative decision
- Neoadjuvant treatment already started
- History of other active cancer
- Known contraindication to a PET examination with injection of radiopharmaceuticals (hypersensitivity to the radiopharmaceutical drug and/or excipients)
- Pregnant or breastfeeding woman
See the full eligibility criteria
- Gastric cancer: stage ≥ II gastric adenocarcinoma or signet-ring cell adenocarcinoma whatever the stage, potentially requiring curative treatment
- Age > 18 years old at time of signed consent
- Beneficiary of social security insurance
- Signed informed consent by the participant and the investigator
- Tumor M+ or with suspicion of distant metastasis on standard assessment
- Person deprived of liberty by judicial or administrative decision
- Neoadjuvant treatment already started
- History of other active cancer
- Known contraindication to a PET examination with injection of radiopharmaceuticals (hypersensitivity to the radiopharmaceutical drug and/or excipients)
- Pregnant or breastfeeding woman
- Woman of childbearing capacity and not benefiting from effective contraception (HAS criterion)
- Person subject to a legal protection measure or unable to personally give consent
- Person in an emergency situation
- Exclusion period from another protocol
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.